Eli Lilly shares rise over 5% on GLP-1-driven Q2 beat
The company's newly launched oral weight-loss drug Foundayo contributed to results, while Novo Nordisk traded lower on the news.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: seekingalpha.com
The wire
- 01Eli Lilly added more than 5% premarket Wednesday after better-than-expected second-quarter 2026 results driven by injectable GLP-1 drugs and the recently launched weight-loss pill Foundayo.
- 02Lilly's incretin franchise performance shapes supply, pricing and formulary dynamics that clinicians and telehealth operators face for semaglutide and tirzepatide alternatives.
- 03The report gives only headline share movement; detailed product-level revenue, guidance changes and Foundayo uptake figures are not stated here.
From the source
Read at seekingalpha.comEli Lilly stock jumps after Q2 beat driven by GLP-1s (LLY:NYSE)
Eli Lilly ( LLY ) added more than 5% in the premarket on Wednesday after reporting better-than-expected Q2 2026 results, driven by its injectable GLP-1 drugs and its newly launched weight-loss pill, Foundayo.
